Citius Pharmaceuticals to Join Benzinga All Access Show on Friday, September 17, 2021
Citius Pharmaceuticals to Join Benzinga All Access Show on Friday, September 17, 2021
CRANFORD, N.J.,Sept. 14, 2021/PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products with a focus on oncology, anti-infective products in adjunct cancer care, unique prescription products and stem cell therapies, today announced that it will be joining Benzinga's All Access Show for a 20-minute interview onFriday, September 17, 2021at10:10 am ET.
新澤西州克蘭福德，9月2021年4月14日/美通社/--花旗製藥公司(Citius PharmPharmticals，Inc.)(以下稱“Citius”或“公司”)(納斯達克股票代碼：CTXR)是一家致力於開發一流危重護理產品並將其商業化的生物製藥公司，專注於腫瘤學、附屬癌症護理中的抗感染產品、獨特的處方藥產品和幹細胞療法。該公司今天宣佈，將參加本辛加的All Access Show節目，訪談時間為20分鐘，時間為美國東部時間2021年9月17日(星期五)上午10：10。
Investors may tune in to the interview with Citius ChairmanLeonard Mazurby visiting Benzinga's livestream channel.
投資者可以收看花旗董事長倫納德·馬祖比(Leonard Mazurby)的採訪，訪問本辛加的直播頻道。
During the interview, Mr. Mazur will discuss advancements in the Company's late-stage clinical pipeline, including the recent addition of I/ONTAK (E7777), a novel oncology asset with an attractive near-term revenue opportunity and substantially de-risked path to support commercial success.
在採訪中，馬祖爾先生將討論該公司晚期臨牀渠道的進展，包括最近增加的I/Ontak(E7777)，這是一項新的腫瘤學資產，具有誘人的近期收入機會和大幅降低風險的途徑，以支持商業成功。
About Citius Pharmaceuticals, Inc.
花旗製藥公司簡介
Citius is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapies. The Company has two late-stage product candidates, Mino-Lok®, an antibiotic lock solution for the treatment of patients with catheter-related bloodstream infections (CRBSIs), which is currently enrolling patients in a Phase 3 Pivotal superiority trial, and I/ONTAK (E7777), a novel IL-2R immunotherapy for an initial indication in cutaneous T-cell lymphoma (CTCL), which has completed enrollment in its Pivotal Phase 3 trial. Mino-Lok®was granted Fast Track designation by the U.S. Food and Drug Administration (FDA). I/ONTAK has received orphan drug designation by the FDA for the treatment of CTCL and peripheral T-cell lymphoma (PTCL). Through its subsidiary, NoveCite, Inc., Citius is developing a novel proprietary mesenchymal stem cell treatment derived from induced pluripotent stem cells (iPSCs) for acute respiratory conditions, with a near-term focus on acute respiratory distress syndrome (ARDS) associated with COVID-19. For more information, please visit www.citiuspharma.com.
Citius是一家晚期生物製藥公司，致力於一流重症護理產品的開發和商業化，專注於腫瘤學、輔助癌症護理中的抗感染藥物、獨特的處方藥和幹細胞療法。該公司有兩個晚期候選產品：Mino-Lok®，這是一種用於治療導管相關血流感染(CRBSI)患者的抗生素鎖定解決方案，目前正在招募患者參加第三階段的關鍵優勢試驗，以及I/Ontak(E7777)，一種新的IL-2R免疫療法，用於皮膚T細胞淋巴瘤(CTCL)的初步適應症，已經完成了其關鍵的3期試驗的登記。Mino-Lok®獲得美國食品和藥物管理局(FDA)的快速通道稱號。I/Ontak已獲得FDA指定的治療CTCL和外周T細胞淋巴瘤(PTCL)的孤兒藥物。通過其子公司NoveCite公司，花旗公司正在開發一種從誘導多能幹細胞中提取的治療急性呼吸疾病的新型專利間充質幹細胞療法，近期的重點是治療與新冠肺炎有關的急性呼吸窘迫綜合徵。欲瞭解更多信息，請訪問www.citiuspharma.com。
Investor Relations for Citius Pharmaceuticals:
Citius製藥公司的投資者關係：
Ilanit Allen
伊蘭尼特·艾倫
Vice President, Corporate Communications and Investor Relations
企業公關和投資者關係部副總裁
T: 908-967-6677 x113
電話：908-967-6677 x113
E: [email protected]
E: [受電子郵件保護]
SOURCE Citius Pharmaceuticals, Inc.Related Links
資料來源：花旗製藥公司(Citius PharmPharmticals，Inc.)相關鏈接
http://www.citiuspharma.com
Http://www.citiuspharma.com
譯文內容由第三人軟體翻譯。